Beta-blockers – can we talk about „class effect”? Review article
Article Sidebar
Published:
Dec 31, 2011
Keywords:
beta-blockers, class effect, evidence based medicine
Main Article Content
Abstract
In the article below the authors attempted to prove lack of „class effect” according to β-adrenolytic agents (β-blockers). Describing specific agents and subgroups they gainsay with some of the standards of European Society of Cardiology.
Article Details
How to Cite
Światowiec , A., Wsół, A., & Kuch , M. (2011). Beta-blockers – can we talk about „class effect”?. Medycyna Faktow (J EBM), 4(4(13), 35-43. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2503
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. ESC Committee for Practice Guidelines: Guidelines on the management of stable angina pectoris. Executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal 2006; 27: 1341-1381.
2. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341-62.
3. Swedberg K., Cleland J., Dargie H. et al.: The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J. 2005; 26: 1115-1140.
4. Hunt S.A., Abraham W.T., Chin M.H. et al., American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: 154-235.
5. Bristow M.R., Port J.D., Kelly R.A.: Treatment of heart failure: pharmacologic methods. W: Heart Disease: A Textbook of Cardiovascular Medicine. Braunwald E., Zippes D.P, Libby P. (red.). Wyd. 6. W.B. Saunders Company, Philadelphia 2001: 562-599.
6. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic Cardiol. 2002; 5: 215-223.
7. Lindholm L.H., Carlberg B., Samuelsson O.: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
8. Mancia G., De Backer G., Dominiczak A. et al.: A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-1187.
9. Rosendorff C., Black H.R., Cannon C.P. et al., American Heart Association Council for High Blood Pressure Research, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention: Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.
10. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 2009; 27: 2121-2158.
11. Law M.R., Morris J.K., Wald N.J.: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1665-1683.
12. Mancia G., Zanchetti A.: Choice of antihypertensive drugs in the European Society of Hypertension – European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J. Hypertens. 2008; 26: 164-168.
13. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 2009; 122: 290-300.
14. Widecka K., Grodzicki T., Narkiewicz K., Tykarski A., Dziwura J. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
15. Bakris G.L., Fonseca V., Katholi R.E. et al., GEMINI Investigators: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236.
16. Cutler J.A., Davis B.R.: Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation 2008; 117: 2691-704.
17. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998; 339: 1759-1765.
18. Malmeberg K.: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI study group. Br. Med. J. 1997; 314: 1512-1515.
19. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002; 106: 394-398.
20. CIBIS II Investigators and Committees: the Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet 1999; 353: 9-13.
21. MERIT – HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL. Randomised Interventional Trial in Congestive Heart Failure (Merit–HF). Lancet 1999; 353: 2001-17.
22. Packer M., Coats A., Fowler M.B. et al., Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001; 344: 1651-1658.
23. Chłopicki S., Kozlovski V.I., Gryglewski R.J.J.: NO-dependent vasodilatation induced by nebivolol in coronary circulation is not mediated by beta-adrenoreceptors or by 5HT-1A receptors. Physiol. Pharmacol. 2002; 53: 615-24.
24. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-577.
25. Yuan Z., Shioji K., Kihara Y. et al.: Cardioprotective effects of carvedilol on acute autoimmune myocarditis anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H83-H90.
26. Brehm B.R., Bertsch D., von Fallois J., Wolf S.C.: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2000; 36: 3401-3403.
27. Falciani M., Rinaldi B., D’Agostino B. et al.: Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 2001; 38: 922-929.
28. Mollnau H., Schulz E., Daiber A. et al.: Nebivolol prevents vascular NOS III uncoupling inexperimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 615-621.
29. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007; 147: 10-18.
30. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
31. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
32. Bertrand M.E., Simoons M.L., Fox K.A. et al.: Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2002; 23: 1809-1840.
33. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N. Engl. J. Med. 1998; 339: 489-497.
34. Flather M.D., Shibata M.C., Coats A.J.S. et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 2005; 26: 215-225.
35. The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA): Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur. Heart J. 2009; 30: 2769-2812.
36. Fleischmann E., Beckman J., Buller Ch. et al.: 2009 ACC/AHA Focused Update on Perioperative Beta Blockade. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2009 Writing Group to Review New Evidence and Update the 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery). J. Am. Coll. Cardiol. 2009; 54: 2102-28.
2. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341-62.
3. Swedberg K., Cleland J., Dargie H. et al.: The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J. 2005; 26: 1115-1140.
4. Hunt S.A., Abraham W.T., Chin M.H. et al., American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: 154-235.
5. Bristow M.R., Port J.D., Kelly R.A.: Treatment of heart failure: pharmacologic methods. W: Heart Disease: A Textbook of Cardiovascular Medicine. Braunwald E., Zippes D.P, Libby P. (red.). Wyd. 6. W.B. Saunders Company, Philadelphia 2001: 562-599.
6. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic Cardiol. 2002; 5: 215-223.
7. Lindholm L.H., Carlberg B., Samuelsson O.: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
8. Mancia G., De Backer G., Dominiczak A. et al.: A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-1187.
9. Rosendorff C., Black H.R., Cannon C.P. et al., American Heart Association Council for High Blood Pressure Research, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention: Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-2788.
10. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 2009; 27: 2121-2158.
11. Law M.R., Morris J.K., Wald N.J.: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1665-1683.
12. Mancia G., Zanchetti A.: Choice of antihypertensive drugs in the European Society of Hypertension – European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J. Hypertens. 2008; 26: 164-168.
13. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 2009; 122: 290-300.
14. Widecka K., Grodzicki T., Narkiewicz K., Tykarski A., Dziwura J. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
15. Bakris G.L., Fonseca V., Katholi R.E. et al., GEMINI Investigators: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236.
16. Cutler J.A., Davis B.R.: Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation 2008; 117: 2691-704.
17. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998; 339: 1759-1765.
18. Malmeberg K.: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI study group. Br. Med. J. 1997; 314: 1512-1515.
19. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002; 106: 394-398.
20. CIBIS II Investigators and Committees: the Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet 1999; 353: 9-13.
21. MERIT – HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL. Randomised Interventional Trial in Congestive Heart Failure (Merit–HF). Lancet 1999; 353: 2001-17.
22. Packer M., Coats A., Fowler M.B. et al., Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001; 344: 1651-1658.
23. Chłopicki S., Kozlovski V.I., Gryglewski R.J.J.: NO-dependent vasodilatation induced by nebivolol in coronary circulation is not mediated by beta-adrenoreceptors or by 5HT-1A receptors. Physiol. Pharmacol. 2002; 53: 615-24.
24. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-577.
25. Yuan Z., Shioji K., Kihara Y. et al.: Cardioprotective effects of carvedilol on acute autoimmune myocarditis anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H83-H90.
26. Brehm B.R., Bertsch D., von Fallois J., Wolf S.C.: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2000; 36: 3401-3403.
27. Falciani M., Rinaldi B., D’Agostino B. et al.: Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 2001; 38: 922-929.
28. Mollnau H., Schulz E., Daiber A. et al.: Nebivolol prevents vascular NOS III uncoupling inexperimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 615-621.
29. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007; 147: 10-18.
30. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
31. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
32. Bertrand M.E., Simoons M.L., Fox K.A. et al.: Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2002; 23: 1809-1840.
33. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N. Engl. J. Med. 1998; 339: 489-497.
34. Flather M.D., Shibata M.C., Coats A.J.S. et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 2005; 26: 215-225.
35. The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA): Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur. Heart J. 2009; 30: 2769-2812.
36. Fleischmann E., Beckman J., Buller Ch. et al.: 2009 ACC/AHA Focused Update on Perioperative Beta Blockade. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2009 Writing Group to Review New Evidence and Update the 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery). J. Am. Coll. Cardiol. 2009; 54: 2102-28.